Director Jason Aryeh filed a Statement of Changes in Beneficial Ownership with the SEC on November 3, 2026, disclosing sales of Ligand Pharmaceuticals Inc common stock on October 30, 2026 and November 2, 2026, along with corrections to previously reported holdings.

Key Highlights

  • Director identity: Jason Aryeh, a director of Ligand Pharmaceuticals Inc (NASDAQ:LGND), is the reporting person.
  • Shares sold on October 30: A total of 1,411 shares of common stock were disposed of across five transactions at prices ranging from $317.74 to $320.49 per share.
  • Shares sold on November 2: An additional 700 shares were sold at a weighted-average price of $320.4261, in multiple transactions at prices ranging from $320.39 to $320.49.
  • Direct holdings after transactions: Following all reported sales, Aryeh directly owned 108,758 shares of common stock.
  • Indirect holdings: An additional 8,000 shares are held indirectly through certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates.
  • Prior filing correction: The filing adjusts holdings reported on a prior filing from June 12, 2026, adding 5,000 shares transferred from indirect to direct ownership and 3,289 previously omitted shares.

Aryeh's October and November 2026 Transactions at Ligand Pharmaceuticals

According to the filing, Jason Aryeh, who serves as a director of Ligand Pharmaceuticals Inc, disposed of common stock on two separate dates. On October 30, 2026, five separate sale transactions were recorded: 50 shares at $317.74, 50 shares at $318.23, 52 shares at $320.24, 1,209 shares at $320.4172, and 50 shares at $320.49, reducing his directly held shares from an adjusted starting figure to 109,458 after those transactions. Ligand Pharmaceuticals is a biopharmaceutical royalty company, and Aryeh's filings reflect his ongoing ownership stake as a board director.

On November 2, 2026, the filing reports an additional sale of 700 shares at a weighted-average price of $320.4261. The filing notes those shares "were sold in multiple transactions at prices ranging from $320.39 to $320.49," and states that Aryeh "undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range." Following this transaction, directly held shares stood at 108,758.

The filing also discloses corrections to Aryeh's previously reported beneficial ownership. The adjustments reflect a transfer of 5,000 shares from JALAA Equities, LP to his direct ownership, described as "exempt from Section 16 pursuant to Rule 16a-13" because it was only "a change in the form of the Reporting Person's beneficial ownership." An additional 3,289 shares are also added to direct ownership, comprising 1,209 shares from vested restricted stock units granted on June 6, 2025 and vested on June 5, 2026, and 2,080 shares held in a brokerage account that were "inadvertently omitted" from the prior total. The 8,000 shares held indirectly through funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates remain unchanged in the current filing.

What Was Disclosed

The filing reports sales of 2,111 shares of Ligand Pharmaceuticals common stock by director Jason Aryeh on October 30 and November 2, 2026, plus corrections to prior ownership figures, leaving him with 108,758 shares held directly and 8,000 held indirectly.